Mesenchymal phenotype predisposes lung cancer cells to impaired proliferation and redox stress in response to glutaminase inhibition

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Ulanet, Danielle B ^a   Couto, Kiley ^a   Jha, Abhishek ^a   Choe, Sung ^a   Wang, Amanda ^a   Woo, Hin Koon ^a   Steadman, Mya ^a   Delabarre, Byron ^a   Gross, Stefan ^a   Driggers, Edward ^a   Dorsch, Marion ^a   Hurov, Jonathan B ^a  

^a AGIOS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIS 2 (5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL)ETHYL SULFIDE; GLUTAMINASE; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; BIS-2-(5-PHENYLACETAMIDO-1,2,4-THIADIAZOL-2-YL)ETHYL SULFIDE; ENZYME INHIBITOR; GLS1 PROTEIN, HUMAN; SULFIDE; THIADIAZOLE DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER SUSCEPTIBILITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; METABOLOMICS; MITOCHONDRIAL RESPIRATION; NON SMALL CELL LUNG CANCER; OXIDATION; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REDOX STRESS; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; GENETIC ASSOCIATION STUDIES; GLUTAMINASE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; SULFIDES; THIADIAZOLES;

EID: 84918523040     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115144     Document Type: Article

References (49)

1. Eagle H, Oyama VI, Levy M, Horton CL, Fleischman R (1956) The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J Biol Chem 218: 607-616.
2. DeBerardinis RJ, Cheng T (2009) Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29: 313-324.
3. Soeters PB, Grecu I (2012) Have we enough glutamine and how does it work? A clinician's view. Ann Nutr Metab 60: 17-26.
4. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ, et al. (2013) Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med 13: 514-534.
5. Williams WJ, Manson LA (1958) Glutaminase of the human malignant cell, strain HeLa. J Biol Chem 232: 229-236.
6. Aledo JC, x000F, mez-Fabre PM, Olalla L, x000Ed,et al. (2000) Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mammalian Genome 11: 1107-1110.
7. van den Heuvel APJ, Jing J, Wooster RF, Bachman KE (2012) Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biology & Therapy 13: 1185-1194.
8. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, et al. (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proceedings of the National Academy of Sciences 105: 18782-18787.
9. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. (2007) Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proceedings of the National Academy of Sciences 104: 19345-19350.
10. Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, et al. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
11. Wang J-B, Erickson JW, Fuji R, Ramachandran S, Gao P, et al. (2010) Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation. Cancer Cell 18: 207-219.
12. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, et al. (2010) Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. Cancer Research 70: 8981-8987.
13. Lobo C, Ruiz-Bellido MA, Aledo JC, Marquez J, Nunez De Castro I, et al. (2000) Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 348 Pt 2: 257-261.
14. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
15. McBryant Steven J, Robinson Mary M, Tsukamoto T, Rojas C, Ferraris Dana V, et al. (2007) Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2- yl)ethyl sulfide (BPTES). Biochemical Journal 406: 407-414.
16. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, et al. (2011) Full-Length Human Glutaminase in Complex with an Allosteric Inhibitor. Biochemistry 50: 10764-10770.
17. Qie S, Chu C, Li W, Wang C, Sang N (2013) ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem.
18. Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22: 396-403.
19. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, et al. (2011) Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proceedings of the National Academy of Sciences 108: 8674-8679.
20. Vincan E, Barker N (2008) The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 25: 657-663.
21. Cheng-Huang Shen J-DW, Yeong-Chin Jou, Ming-Chin Cheng, Chang-Te Lin,, Pi-Che Chen Y-ST, Chung-Sheng Shi, Syue-Yi Chen, De-Ching Chang,, Lee Y-R (2011) The correlation between TWIST, E-cadherin, and beta-catenin in human bladder cancer. Journal of BUON 16: 733-737.
22. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ (2008) Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol 38: 95-104.
23. Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. Biochem J 435: 297-312.
24. Diers AR, Broniowska KA, Chang CF, Hogg N (2012) Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem J 444: 561-571.
25. Le A, Lane AN, Hamaker M, Bose S, Gouw A, et al. (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15: 110-121.
26. Grant CM (2008) Metabolic reconfiguration is a regulated response to oxidative stress. J Biol 7: 1.
27. Gameiro PA, Yang J, Metelo AM, Perez-Carro R, Baker R, et al. (2013) In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17: 372-385.
28. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, et al. (2010) The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 24: 2784-2799.
29. Andratsch M, Feifel E, Taylor L, O'Hayre M, Schramek H, et al. (2007) TGF-beta signaling and its effect on glutaminase expression in LLC-PK1-FBPase+ cells. Am J Physiol Renal Physiol 293: F846-853.
30. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, et al. (2011) A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 28: 137-155.
31. Simpson NE, Tryndyak VP, Beland FA, Pogribny IP (2011) An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Research and Treatment 133: 959-968.
32. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, et al. (2010) TGF- IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences 107: 15535-15540.
33. Lin CC, Cheng TL, Tsai WH, Tsai HJ, Hu KH, et al. (2012) Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Sci Rep 2: 785.
34. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.
35. Barr S, Thomson S, Buck E, Russo S, Petti F, et al. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 25: 685-693.
36. Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, et al. (2012) Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol 227: 1709-1720.
37. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
38. Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, et al. (2012) Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem 287: 42180-42194.
39. Sobhakumari A, Love-Homan L, Fletcher EV, Martin SM, Parsons AD, et al. (2012) Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One 7: e48175.
40. Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, et al. (2013) Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. J Biol Chem 288: 770-777.
41. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, et al. (2005) NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900-907.
42. Gorowiec MR, Borthwick LA, Parker SM, Kirby JA, Saretzki GC, et al. (2012) Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-beta1-dependent mechanism. Free Radic Biol Med 52: 1024-1032.
43. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, et al. (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proceedings of the National Academy of Sciences 107: 7461-7466.
44. Brodie AE, Reed DJ (1990) Cellular recovery of glyceraldehyde-3-phosphate dehydrogenase activity and thiol status after exposure to hydroperoxides. Arch Biochem Biophys 276: 212-218.
45. Vaidyanathan VV, Sastry PS, Ramasarma T (1993) Regulation of the activity of glyceraldehyde 3- phosphate dehydrogenase by glutathione and H2O2. Mol Cell Biochem 129: 57-65.
46. Foroni C, Broggini M, Generali D, Damia G (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 38: 689-697.
47. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, et al. (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13: 890-901.
48. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, et al. (2013) Glutamine sensitivity analysis identifies the xCTantiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24: 450-465.
49. Melamud E, Vastag L, Rabinowitz JD (2010) Metabolomic analysis and visualization engine for LC-MS data. Anal Chem 82: 9818-9826.